Codexis to Report Second Quarter 2026 Financial Results on August 11

Rhea-AI Summary

Codexis (NASDAQ: CDXS) announced it will report Q2 2026 financial results on Tuesday, August 11, 2026, after the market close. Management will host a conference call and webcast at 4:30 p.m. Eastern Time to review results and provide a business update.

Investors can access the live webcast via the Codexis Investor Relations website, with an archive available for 90 days. The live call is available at 877-705-2976 (domestic) or 201-689-8798 (international). A 48-hour telephone replay will be offered at 877-660-6853 (domestic) or 201-612-7415 (international), access ID 13726635.

Market Context

The two prior earnings-date notices were followed by 2.02% and 1.36% 24-hour reactions. That record ...

Analysis

The two prior earnings-date notices were followed by 2.02% and 1.36% 24-hour reactions. That record adds context to the scheduled report, while recent insider data showed Net Selling and no reported purchases.

Key Figures

Reporting period: Q2 2026 Results date: August 11, 2026 Conference call time: 4:30 pm Eastern Time +2 more

5 metrics

Reporting period Q2 2026 Financial results to be reported

Results date August 11, 2026 Following the close of market

Conference call time 4:30 pm Eastern Time Management discussion and business update

Webcast archive 90 days Investor Relations website archive

Telephone replay 48 hours Post-call telephone replay availability

Previous Earnings date Reports

2 past events · Latest: Apr 23 (Neutral)

Same Type Pattern 2 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 23	Q1 earnings date	Neutral	+2.0%	Announced Q1 2026 results date and post-market conference call
Feb 25	FY2025 earnings date	Neutral	+1.4%	Announced fourth-quarter and fiscal-year results date and webcast

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

The two prior earnings-date announcements were followed by positive 24-hour reactions of 2.02% and 1.36%.

Key Terms

rnai therapeutics, nucleic acid synthesis

2 terms

rnai therapeutics medical

"enable the scaled manufacture of RNAi therapeutics through an enzymatic route"

RNAi therapeutics are medicines that harness a natural cell process called RNA interference to silence specific genes by destroying or blocking the messenger RNA that carries instructions for making a protein—think of removing a recipe from a cookbook so the dish is no longer made. Investors care because this approach can create highly targeted treatments for diseases, offering potential for breakthrough drugs, faster development paths and distinct market or patent advantages, while carrying technical and regulatory risks.

nucleic acid synthesis technical

"small molecule pharmaceuticals manufacturing and nucleic acid synthesis"

Nucleic acid synthesis is the biological or laboratory process of building DNA or RNA, the molecules that store and carry genetic instructions—think of it as writing or copying the recipe book that controls cells. Investors care because the ability to design, manufacture or manipulate these molecules underpins many drugs, vaccines, diagnostic tests and gene therapies; improvements or setbacks in this capability can change development timelines, costs, regulatory risk and market potential.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

REDWOOD CITY, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced that it will report its financial results for the second quarter of 2026 on Tuesday, August 11, 2026, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company’s financial results and provide a business update.

Participants may access the live webcast on the Codexis Investor Relations website, where it will be archived for 90 days. The live call can be accessed by dialing 877-705-2976 (domestic) or 201-689-8798 (international). A telephone replay of the call will be available for 48 hours by dialing 877-660-6853 (domestic) or 201-612-7415 (international), access ID #13726635.

About Codexis

Codexis® is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, leveraging its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis® manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis’ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. For more information, visit https://www.codexis.com.

For More Information
Investor Contact
Georgia Erbez
(650) 421-8100
ir@codexis.com

FAQ

When will Codexis (NASDAQ: CDXS) report its Q2 2026 earnings results?

Codexis will report its Q2 2026 financial results on Tuesday, August 11, 2026, after market close. According to Codexis, this release will be followed by a management conference call and webcast at 4:30 p.m. Eastern Time the same day.

What time is the Codexis (CDXS) Q2 2026 earnings conference call on August 11, 2026?

The Codexis Q2 2026 earnings conference call is scheduled for 4:30 p.m. Eastern Time on August 11, 2026. According to Codexis, the call will follow the financial results release after market close and include a business update.

How can investors access the Codexis (CDXS) Q2 2026 earnings webcast?

Investors can access the Codexis Q2 2026 earnings webcast via the Codexis Investor Relations website. According to Codexis, the live webcast will also be archived on the site for 90 days after the event for on-demand replay.

What are the dial-in numbers for the Codexis (CDXS) Q2 2026 earnings call?

The live Codexis Q2 2026 earnings call can be joined by dialing 877-705-2976 (domestic) or 201-689-8798 (international). According to Codexis, these numbers provide direct access to the results discussion and business update.

Is there a telephone replay for the Codexis (CDXS) Q2 2026 earnings call?

Yes, a telephone replay will be available for 48 hours after the Codexis Q2 2026 call. According to Codexis, investors can dial 877-660-6853 (domestic) or 201-612-7415 (international) and enter access ID 13726635.

Where can I find more information about Codexis (CDXS) and its technology platforms?

More information about Codexis and its enzymatic solutions is available at https://www.codexis.com. According to Codexis, the company leverages its CodeEvolver and ECO Synthesis platforms for therapeutics manufacturing and RNAi therapeutics scale-up.